|
KS-Detect: A solar-powered and smartphone integrated instrument for point-of-care
|
1R43CA193096-01
|
$224,835
|
$224,835
|
JIANG, LI
|
A'AS, INC.
|
|
Therapeutic Vaccine Targeting CMV Antigens in Glioblastoma
|
2R42CA153845-02
|
$1,227,385
|
$1,227,385
|
SAMPSON, JOHN
|
ANNIAS IMMUNOTHERAPEUTICS, INC.
|
|
An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re
|
5R42CA183708-04
|
$499,411
|
$249,706
|
PARSONS, CHRISTOPHER
|
APOGEE BIOTECHNOLOGY CORPORATION
|
|
A prospective analysis of peripheral blood cytokines and non-Hodgkin lymphoma
|
5R01CA149445-05
|
$738,521
|
$738,521
|
BIRMANN, BRENDA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Investigating the cytomegalovirus link to glioblastoma using a novel mouse model
|
1R01CA195532-01
|
$396,329
|
$396,329
|
CHIOCCA, E.
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Genetic and Biochemical Studies of KSHV LANA
|
2R01CA082036-16A1
|
$420,869
|
$420,869
|
KAYE, KENNETH
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Epstein-Barr Virus Nuclear Protein in B Cell Growth Transformation
|
5R01CA047006-28
|
$565,231
|
$565,231
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Epstein-Barr Virus LMP1-Mediated Oncogenecity
|
5R01CA085180-14
|
$701,405
|
$701,405
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Roles of Epstein-Barr virus nuclear antigens 2 and LP in B cell proliferation
|
5R01CA170023-03
|
$392,517
|
$392,517
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Control of CMV infection post-HCT using attenuated MVA-based CMV subunit vaccine
|
5R01CA077544-14
|
$533,838
|
$533,838
|
DIAMOND, DON
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
City of Hope Lymphoma SPORE
|
5P50CA107399-10
|
$2,185,000
|
$65,550
|
FORMAN, STEPHEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-32S1
|
$113,085
|
$3,393
|
ROSEN, STEVEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-32S2
|
$53,400
|
$1,602
|
ROSEN, STEVEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-32S3
|
$50,000
|
$1,500
|
ROSEN, STEVEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-32S4
|
$124,999
|
$3,750
|
ROSEN, STEVEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
5P30CA033572-32
|
$2,184,600
|
$65,538
|
ROSEN, STEVEN
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA006516-50S1
|
$122,500
|
$3,675
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S2
|
$50,000
|
$1,500
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S3
|
$125,000
|
$3,750
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S4
|
$200,000
|
$6,000
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-50S5
|
$62,500
|
$1,875
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
5P30CA006516-50
|
$11,162,542
|
$334,876
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Complementary Signaling Pathways In Hodgkin Lymphoma and Related Malignancies
|
5R01CA161026-05
|
$425,165
|
$106,291
|
SHIPP, MARGARET
|
DANA-FARBER CANCER INST
|
|
Viral Oncology Training Grant
|
5T32CA009111-37
|
$373,216
|
$111,965
|
CULLEN, BRYAN
|
DUKE UNIVERSITY
|
|
Cancer Center Support Grant
|
2P30CA014236-41
|
$5,661,203
|
$113,224
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
|
Cancer Center Support Grant
|
3P30CA014236-41S1
|
$56,234
|
$1,125
|
KASTAN, MICHAEL
|
DUKE UNIVERSITY
|
|
Host pathways regulating Epstein-Barr virus-mediated B cell growth transformation
|
3R01CA140337-05S1
|
$66,880
|
$66,880
|
LUFTIG, MICAH
|
DUKE UNIVERSITY
|
|
Host pathways regulating Epstein-Barr virus-mediated B cell growth transformation
|
5R01CA140337-05
|
$325,775
|
$325,775
|
LUFTIG, MICAH
|
DUKE UNIVERSITY
|
|
Temporal regulation of the essential Epstein-Barr virus oncoprotein LMP1
|
5F31CA180451-03
|
$33,389
|
$33,389
|
PRICE, ALEXANDER
|
DUKE UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-07S1
|
$37,430
|
$749
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
5P30CA138292-07
|
$1,560,000
|
$31,200
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Role of B cells in murine gammaherpesvirus 68
|
2R01CA095318-11A1
|
$368,305
|
$368,305
|
SPECK, SAMUEL
|
EMORY UNIVERSITY
|
|
Manipulation of kinase signaling by the human oncovirus KSHV
|
5F31CA183250-02
|
$35,875
|
$35,875
|
AVEY, DENIS
|
FLORIDA STATE UNIVERSITY
|
|
Exosome-Dependent Trafficking of Epstein-Barr Virus LMP1
|
1R15CA188941-01A1
|
$414,462
|
$414,462
|
MECKES, DAVID
|
FLORIDA STATE UNIVERSITY
|
|
Biologic Determinants of the Natural History of AIDS-Defining Cancers in Uganda
|
5U54CA190146-02
|
$780,706
|
$359,125
|
CASPER, COREY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Human Herpesvirus-8 Replication and Kaposi Sarcoma Response to Treatment
|
5K23CA150931-05
|
$142,035
|
$142,035
|
PHIPPS, WARREN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Plasma and serum biomarkers for Hodgkin lymphoma
|
5R21CA188824-02
|
$178,438
|
$44,610
|
AMBINDER, RICHARD
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
3P30CA006973-52S1
|
$31,250
|
$313
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
3P30CA006973-52S2
|
$125,000
|
$1,250
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
3P30CA006973-52S3
|
$185,800
|
$1,858
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
5P30CA006973-52
|
$6,995,267
|
$69,953
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
HHV-8 vIRF interactions in the context of infection
|
1R21CA196348-01A1
|
$176,175
|
$176,175
|
NICHOLAS, JOHN
|
JOHNS HOPKINS UNIVERSITY
|
|
INCREMENTAL SEVERABLE FUNDING FOR THE NCI AT FREDERICK
|
261200800001E
|
$205,925,847
|
$4,705
|
HEIMBROOK, DAVID
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
Experimental Therapeutics and BioMonitoring for Brain Tumors
|
5P01CA069246-18
|
$1,332,561
|
$319,815
|
BREAKEFIELD, XANDRA
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Novel oncolytic HSV-1 therapy for breast cancer meningeal metastases
|
5R21CA186054-02
|
$189,093
|
$189,093
|
KURUPPU, KUMUDU
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Targeting Tumorigenic Pathways in Glioblastoma with Oncolytic HSV
|
5R01CA160762-04
|
$355,522
|
$355,522
|
RABKIN, SAMUEL
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
ATM and gammaherpesvirus infection: a precarious balance
|
5R01CA183593-02
|
$317,475
|
$317,475
|
TARAKANOVA, VERA
|
MEDICAL COLLEGE OF WISCONSIN
|
|
The Function of EBV LMP1 CTAR3 in Sumoylation and Oncogenesis
|
5R00CA160786-03
|
$249,000
|
$249,000
|
BENTZ, GRETCHEN
|
MERCER UNIVERSITY MACON
|
|
Receptor Mediated SPECT Imaging Of Kaposi Sarcoma With 99mTc-Tilmanocept
|
1R44CA192859-01A1
|
$300,000
|
$300,000
|
COPE, FREDERICK
|
NAVIDEA BIOPHARMACEUTICALS, INC.
|
|
Hematopathology Diagnosis
|
ZIA BC 011070
|
$685,442
|
$68,544
|
Jaffe, Elaine
|
CCR (NCI)
|
Total relevant funding to Herpes - Other for this search: $44,620,533
|